Search results
Results from the WOW.Com Content Network
Diffuse large B-cell lymphoma (DLBCL) is a cancer of B cells, a type of lymphocyte that is responsible for producing antibodies.It is the most common form of non-Hodgkin lymphoma among adults, [1] with an annual incidence of 7–8 cases per 100,000 people per year in the US and UK.
FA-DLBCL also differs from DLBCLCI in that it usually presents as infiltrates rather than tumors and is a far less aggressive and in many cases a relatively benign disease. [14] Here, it is considered in the differential diagnosis of DLBCL-CI and more fully described elsewhere (see fibrin-associated diffuse large B-cell lymphoma).
Micrograph showing Hodgkin's lymphoma, a type of B cell lymphoma that is usually considered separate from other B cell lymphomas. Field stain. CT scan of primary B cell lymphoma in the left ilium, as diffuse cortical and trabecular thickening of the hemipelvis, mimicking Paget's disease.
Primary central nervous system lymphoma (PCNSL), also termed primary diffuse large B-cell lymphoma of the central nervous system (DLBCL-CNS), [2] is a primary intracranial tumor appearing mostly in patients with severe immunodeficiency (typically patients with AIDS). It is a subtype and one of the most aggressive of the diffuse large B-cell ...
It has a 5-year overall survival rate of 40–55%, although the PCDLBCL-O variant has a better prognosis than cases in which the legs are involved. [ 5 ] Most lymphomas begin in a lymph node , mucosa-associated lymphoid tissue , the spleen , or another lymphoid tissue within the lymphatic system and then may spread to the skin.
Aggressive lymphoma, also known as high-grade lymphoma, is a group of fast growing non-Hodgkin lymphoma. [1]There are several subtypes of aggressive lymphoma. These include AIDS-associated lymphoma, angioimmunoblastic lymphoma, Burkitt lymphoma, central nervous system (CNS) lymphoma, diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and peripheral T-cell lymphoma. [1]
A study of DLBCL cell lines indicated that 14-3-3ζ proteins may play a role in mediating resistance of DLBCL cells to CHOP. 14-3-3 proteins exert anti-apoptotic activity by interfering with the function of BH3-only proteins and has been validated as a potential molecular target for anticancer therapeutic development in other types of cancers.
Individuals with FA-DLBCL are typically males (~70% of cases) aged 25–96 years (~75% of cases are >50 years old). [6] They present with abnormalities associated with a long-standing (1–20 years [6]): a) cardiac myxoma (i.e. a myxoid tumor of primitive connective tissue in the heart's atrium); b) subdural hematoma (i.e. a collection of blood between the inner layer of the dura mater and the ...